CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 222 enrolled
Drug / intervention
Methylphenidate +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01133847
NCT01133847Phase 4Completed

Reading ICARD: Interventions for Children With Attention and Reading Disorders

The University of Texas Health Science Center, Houston·interventional·Posted May 31, 2010·Updated Apr 11, 2017

In Brief

A Phase 4 clinical trial evaluating Methylphenidate, Intensive reading instruction, and 4 other interventions for Attention Deficit Hyperactivity Disorder and Reading Disabilities. Completed, enrolled 222 participants across 2 sites.

Detailed Summary

The objective of this randomized clinical trial is to address unanswered questions about the relative effectiveness of treatments for children with both Attention Deficit Hyperactivity Disorder (ADHD) and significant reading difficulties (RD). The study evaluates attentional and word reading outcomes for students with both conditions when provided with either (a) ADHD treatment alone, (b) RD treatment alone, or (c) the combination of ADHD and RD treatment.

Study Details

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 31, 2010
Enrollment StartNov 1, 2010
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 16.1 years ago

Interventions

Methylphenidatedrug

Appropriate dosage to be individually determined; daily for 16 weeks

Intensive reading instructionbehavioral

Individualized phonologically-based instruction delivered 4 days per week for 45 min. per day by a highly trained tutor.

Parent Trainingbehavioral

Nine sessions on parenting a child with ADHD

Mixed Salt Amphetaminedrug

Appropriate dosage to be individually determined; daily for 16 weeks; prescribed only if child does not show a beneficial treatment response to Concerta

Atomoxetinedrug

Appropriate dosage to be individually determined; daily for 16 weeks

Guanfacinedrug

Appropriate dosage to be individually determined; daily for 16 weeks